These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus. Sellam J; Miceli-Richard C; Gottenberg JE; Ittah M; Lavie F; Lacabaratz C; Gestermann N; Proust A; Lambotte O; Mariette X Ann Rheum Dis; 2007 Jun; 66(6):790-7. PubMed ID: 17185325 [TBL] [Abstract][Full Text] [Related]
10. Expression of interferon regulatory factor 1, 3, and 7 in primary Sjögren syndrome. Zheng L; Yu C; Zhang Z; Yang C; Cai X Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 May; 107(5):661-8. PubMed ID: 19426920 [TBL] [Abstract][Full Text] [Related]
11. Alterations of cerebral cortex and hippocampal proteasome subunit expression and function in a traumatic brain injury rat model. Yao X; Liu J; McCabe JT J Neurochem; 2008 Jan; 104(2):353-63. PubMed ID: 17944870 [TBL] [Abstract][Full Text] [Related]
12. Methylation profile of the promoter region of IRF5 in primary Sjögren's syndrome. Gestermann N; Koutero M; Belkhir R; Tost J; Mariette X; Miceli-Richard C Eur Cytokine Netw; 2012; 23(4):166-72. PubMed ID: 23302156 [TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma. Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533 [TBL] [Abstract][Full Text] [Related]
14. Effect of noncompetitive proteasome inhibition on bortezomib resistance. Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154 [TBL] [Abstract][Full Text] [Related]
15. Complement factor C3a alters proteasome function in human RPE cells and in an animal model of age-related RPE degeneration. Ramos de Carvalho JE; Klaassen I; Vogels IM; Schipper-Krom S; van Noorden CJ; Reits E; Gorgels TG; Bergen AA; Schlingemann RO Invest Ophthalmol Vis Sci; 2013 Oct; 54(10):6489-501. PubMed ID: 23982842 [TBL] [Abstract][Full Text] [Related]
16. B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjögren's syndrome. Lavie F; Miceli-Richard C; Ittah M; Sellam J; Gottenberg JE; Mariette X Scand J Immunol; 2008 Feb; 67(2):185-92. PubMed ID: 18201372 [TBL] [Abstract][Full Text] [Related]
17. Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer. de Wilt LH; Jansen G; Assaraf YG; van Meerloo J; Cloos J; Schimmer AD; Chan ET; Kirk CJ; Peters GJ; Kruyt FA Biochem Pharmacol; 2012 Jan; 83(2):207-17. PubMed ID: 22027222 [TBL] [Abstract][Full Text] [Related]
18. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells. Fuchs D; Berges C; Opelz G; Daniel V; Naujokat C J Cell Biochem; 2008 Jan; 103(1):270-83. PubMed ID: 17516511 [TBL] [Abstract][Full Text] [Related]
19. Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors. Niewerth D; Franke NE; Jansen G; Assaraf YG; van Meerloo J; Kirk CJ; Degenhardt J; Anderl J; Schimmer AD; Zweegman S; de Haas V; Horton TM; Kaspers GJ; Cloos J Haematologica; 2013 Dec; 98(12):1896-904. PubMed ID: 24056819 [TBL] [Abstract][Full Text] [Related]